Laboratory News Items:
September 2022:
Dr. Xu and Dr. Hedden awarded 2022 Research Scholar Award from the Friedman Brain Institute
Dr. Xiang Xu and Dr. Trey Hedden were awarded the Jane Martin and Stuart Katz Research Scholar Award by the Friedman Brain Institute at the Icahn School of Medicine at Mount Sinai for their collaborative project titled “In vivo measurement of Aβ in preclinical Alzheimer’s Disease by saturation transfer MRI”. Research Scholars are selected on a competitive basis by an expert review committee led by the Director of the Friedman Brain Institute who ensures that the process is objective, thorough and achieves the right balance of support for basic, clinical and translational research. Read the full announcement of the 2022 Research Scholar Awards here:
2022 Research Scholar Awards
March 2021:
Gift Establishes Sanford Grossman Interdisciplinary Center in Neural Circuitry and Immune Function at the Icahn School of Medicine at Mount Sinai
The Center will leverage the unique capabilities of Mount Sinai’s leading experts in Alzheimer’s disease, genetics, stem cells, imaging, clinical neurology, neuropathology and the Mount Sinai BioMe biobank to create tools for early diagnosis, and to uncover novel mechanisms of Alzheimer’s disease that can aid in the development of therapeutics for this devastating and widespread disease. “Alzheimer’s disease causes progressive damage to the brain over relatively long periods of time so early diagnosis and treatment is crucial,” said Dr. Grossman, a renowned economist and philanthropist. “We hope to develop tools for early diagnosis and for early measurement of disease progression before cognitive decline appears. We also hope to elucidate the role of mis-regulated immune response in the course of the disease.”
December 2020:
Dr. Hedden named as a Highly Cited Researcher by Web of Science:
Dr. Hedden’s articles were cited by other researchers over 1200 times in 2020. See the full list of highly cited researchers here:
September 2020:
Article published in Neuroimage:Clinical:
In a collaborative effort, Dr. Hedden’s team examined 250 older adults followed for an average of 5.2 years to determine what neuroimaging markers would best predict progression from normal cognition to mild cognitive impairment (MCI). Among a large set of potential markers, greater brain amyloid levels, lower thickness of the entorhinal cortex, smaller volume of the hippocampus, and lower connectivity in a specific brain network best predicted progression to MCI. Notably, these brain markers predicted progression even when accounting for cognitive predictors. This may provide an efficient set of brain markers that can be used to help assess risk for progression to MCI.
Full article can be accessed at Neuroimage:Clinical.
The data analyzed were from the Harvard Aging Brain Study.
April 2019:
Mount Sinai awarded an Inaugural NYFIRST Grant to support research infrastructure for Dr. Hedden’s research on aging and Alzheimer’s Disease:
Mount Sinai received a grant from the New York Fund for Innovation in Research and Scientific Talent (NYFIRST) associated with the recruitment of Dr. Hedden. This funding program encourages recruitment and retention of exceptional life science researchers working in translational research.
Mount Sinai NYFIRST Press Release
NYFIRST Announcement from Governor’s Office